Related Experiment Video
Updated: May 19, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Association between the CTGF -945C/G polymorphism and systemic sclerosis: a meta-analysis.
Xiufeng Zhang1, Shengjie Nie, Xiaoyu Si
1School of Forensic Medicine, Kunming Medical University, Kunming, Yunnan 650500, China. xiuzheng1203@163.com
Gene
|August 22, 2012
Summary
The connective tissue growth factor (CTGF) -945C/G polymorphism may decrease systemic sclerosis risk in Asians. Further global studies are needed to confirm this association between CTGF polymorphism and systemic sclerosis.
Area of Science:
- Genetics
- Rheumatology
- Epidemiology
Background:
- Conflicting evidence exists regarding the association between the connective tissue growth factor (CTGF) -945C/G polymorphism and systemic sclerosis risk.
- Previous studies have yielded inconsistent results, necessitating further investigation.
Purpose of the Study:
- To perform a meta-analysis to validate the association between the CTGF -945C/G polymorphism and the risk of developing systemic sclerosis.
- To clarify the role of this genetic variant in systemic sclerosis susceptibility.
Main Methods:
- A systematic electronic search of PubMed was conducted to identify relevant case-control studies.
- Studies with available genotype frequencies for the CTGF -945C/G polymorphism were included.
- Odds ratios (OR) and 95% confidence intervals (CI) were calculated to assess the strength of the association.
Main Results:
- Six case-control studies comprising 3335 cases and 3589 controls were analyzed.
- Overall, the CTGF -945C/G polymorphism was not significantly associated with systemic sclerosis risk (OR=0.947, 95% CI: 0.792-1.132).
- Stratified analysis revealed that the CC/CG genotype significantly decreased systemic sclerosis susceptibility in Asians (OR=0.632, 95% CI: 0.459-0.869) under a dominant model, while no association was found in Caucasians.
Conclusions:
- This meta-analysis suggests that the CC/CG genotype of the CTGF -945C/G polymorphism is associated with a reduced risk of systemic sclerosis in Asian populations.
- Larger, prospective global studies are recommended to further investigate the relationship between CTGF -945C/G polymorphism and systemic sclerosis, particularly in diverse subpopulations.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...